Aquestive Therapeutics Inc. is advancing its global expansion strategy for Anaphylm, its non-invasive epinephrine therapy for severe allergic reactions. The company has initiated regulatory engagements in Canada, Europe, and the United Kingdom, with plans to submit a New Drug Submission to Health Canada in the first half of 2026 and a marketing authorization application in Europe in the second half of 2026. Aquestive is also awaiting feedback from the UK's Medicines and Healthcare Products Regulatory Agency in early 2026. These efforts aim to expand access to Anaphylm internationally. Additionally, the company plans to hire a U.S. sales force following potential FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622687-en) on January 09, 2026, and is solely responsible for the information contained therein.